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CASE REPORT
INTRODUCTION
The use of hyperbaric oxygen therapy (HBO) has been a 
widely-accepted form of treatment for certain conditions. 
Hyperbaric oxygen therapy involves the inhalation of 100% 
oxygen in a hyperbaric chamber at a pressure higher than 1 
atm or 760 mmHg. The beneficial effects of HBO results from 
generating physiologic hyperoxia in tissue by fully saturating 
hemoglobin molecules and increasing the amount of oxygen 
dissolved in the plasma. This allows tissue to meet its oxygen 
demand through the dissolved oxygen alone without the need 
to utilize the oxygen linked to hemoglobin.1-5 As a class II 
medical device, hyperbaric chambers are currently approved 
for 13 indications by the U.S. Food and Drug Administration 
(FDA) and Hyperbaric Medical Society.6,7 Indications currently 
include adjuvant therapy in wound ischemia, thermal burn 
treatment, blood loss anemia, air embolisms, carbon monoxide 
poisoning, clostridial myonecrosis, crush injury, decompres-
sion sickness, chronic refractory osteomyelitis, necrotizing 
soft-tissue infections, radiation tissue injury, ischemic skin 
grafts and flaps, and intracranial abscess (Table 1), but does 
not include neurologic conditions.5,8-10 The 2016 European 
Consensus Conference on Hyperbaric Medicine resulted in a 
list of 9 indications for HBO to be used as a primary therapy, 
with an additional 13 indications where there is acceptable 
evidence that HBO may be used as treatment, as well as 6 indi-
cations where HBO may be considered as an optional modality. 
Amongst the 13 FDA-approved indications and the 28 indica-
tions that resulted from the 2016 European Consensus Confer-
ence on Hyperbaric Medicine, neither group includes treatment 
for neurological conditions such as migraines with aura.5,8,9,11 
Current treatments for migraines and other headaches are 
based around relieving the symptoms through the reduction of 
cerebral blood flow.12 HBO substantially increases the amount 
of arterial oxygen and therefore effectively achieves cerebral 
vasoconstriction, thus treating the migraine.1,13 Based on this 
case report, we believe the current approved indications for 
HBO need to be expanded to include resistant migraines after 
further randomized control trials demonstrate efficacy in a 
larger patient population (Table 1).
CASE HISTORY
We present a 23-year-old female with a self-reported history 
of migraines with aura since the age of 12 with no other rel-
evant medical history. She described her migraines as severe 
in nature lasting 4–6 hours, 3 times monthly on average. Her 
extreme pain and sensitivity to light and sound often impaired 
daily function, causing a loss of vision and inability to focus 
on tasks at hand. The patient also reported frequent abdominal 
pain leading to emesis during her migraine attacks. Overall, 
the migraines hindered her functional status as she had missed 
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Table 1: Current U.S. Food and Drug Administration 
approved indications and recommended update to the 
current indications for hyperbaric oxygen therapy6,7
No. Indications




2 Carbon monoxide poisoning
3 Gas gangrene
4 Crush injury/compartment 
syndrome
5 Decompression sickness
6 Healing of complicated wounds




11 Delayed radiation soft tissue injury
12 Compromised skin grafts
13 Thermal burns




16 Other neurological conditions
many days of school and work due to her condition. She had 
been managed by her primary care physician since the onset 
of her migraines at an early age; however, she experienced 
migraines refractory to Imitrix and adjustments to birth control. 
The patient would typically get mild relief using Excedrin, 
caffeine consumption, removal of light, and use of ice packs. 
Evaluation of this patient prior to initiation of treatment re-
vealed no contraindications to HBO. The patient underwent 
treatment at 1.5 absolute atmospheres in a hyperbaric chamber 
Monday through Friday for 1 hour each day, for a total of 40 
sessions, but reported missing a few sessions over the 8-week 
period. No more than one session during a given week was 
missed and the patient received no other treatments for her 
migraines throughout this time period. By her 24th treatment, 
the patient had only experienced a single migraine with aura 
but without debilitating pain. The patient stated she has never 
had a migraine with such little intensity prior to initiation of 
hyperbaric treatment and did not have to take any days off from 
work or school during treatment. Follow-up at the end of her 
40-day treatment period revealed a highly-satisfied patient who 
had only experienced the single episode of a mild migraine 
during the entire course of treatment. It is important to indicate 
that the patient did not receive any additional therapy during 
HBO treatments. 
DISCUSSION
The most recent guidelines for management of acute migraine 
attacks involve use of triptans, non-steroidal anti-inflammatory 
drugs and antiemetics. Prophylactic treatment often includes 
the use of beta blockers, tricyclic antidepressants, and anti-
convulsants. Response to such therapies is highly variable and 
is often effective only in a select group of patients. They are 
often prescribed based upon the patient’s tolerability of the 
medication and comorbid conditions. Migraine attacks with 
aura are often less responsive to triptans and carry an even 
more differentiated response when compared to a migraine 
without aura.12,14 Thus, a great need for alternative treatments 
for migraines exists, especially for patients whose migraines 
are refractory to current pharmacologic therapies. 
As illustrated by this report, HBO may provide a novel ap-
proach in reducing the disability of the migraineur by providing 
relief, and by reducing the frequency of attacks refractory to 
pharmacologic therapy. While the exact inflammatory media-
tors responsible for migraine headaches are still unknown, it 
is known that inflammation plays a role in the activation of 
the trigeminovascular system leading to migraines with the 
characteristic throbbing pain.13,15,16 The peripheral activation 
of the trigeminovascular nociceptors in the dura mater leads 
the release of vasoactive dilators including calcitonin gene-
related peptide causing long lasting stimulation and vasodi-
lation.16-18 The beneficial effects of HBO are caused through 
the physiologic consequences of 100% inspired oxygen and 
exposure to elevated atmospheric pressures. This leads to 
higher levels of dissolved oxygen in plasma and subsequent 
arterial constriction in the brain, thus aborting and preventing 
the migraine.1-4,15,19 
The current understanding of the pathophysiology behind 
migraines with aura combined with the increasing evidence 
supporting the anti-inflammatory and anti-vasodilatory effects 
of HBO, suggests that our patients’ relief could be related to 
HBO decreasing the inflammatory response that leads to the 
activation of the trigeminovascular pathway.10,13,15,20 A study 
by Myers et al.21 demonstrated a significant reduction (P < 
0.05) in migraine relief in patients undergoing HBO versus 
those who underwent normobaric oxygen therapy. Wilson et 
al.15 showed a significant decrease in subjective pain in those 
who underwent HBO versus the control group of females with 
migraine with aura. Other studies by Eftedal et al.1,22,23 showed 
insignificant prophylactic measure against migraines with the 
use of HBO. It is important to note that these studies have 
limited sample sizes. A Cochrane review on the usage of HBO 
to prevent migraines showed no evidence to suggest that HBO 
could prevent migraine attacks, reduce the incidence of nausea 
and vomiting, or reduce the requirement for rescue medication 
based upon 11 trials.23 On the contrary, we present a patient 
who had a reduction in frequency, intensity, symptomatology, 
and need for rescue medications after HBO treatment. To 
truly judge the efficacy of HBO and take to into account the 
inherent variability in response to different treatments, larger 
studies are needed. Our case of this 23-year-old female who 
experienced a reduction in the frequency and intensity of her 
migraines after HBO provides the evidence for the use of 
HBO in the management of chronic migraine. Of note, there 
has been a limited follow up time with the patient so we are 
unable to determine how long this treatment modality will 
remain effective in the long term. The purpose of this article 
is to expand the currently FDA-approved indications for HBO, 
such as migraine, headaches based on randomized controlled 
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studies addressing long lasting efficacy in large patient popula-
tions. While there has been progress both in the understanding 
of migraine pathophysiology and the mechanism of action of 
HBO over the past few years, further research is needed to 
expand our knowledge and create better treatments for patients 
with migraines.
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